Natera, Inc. (NASDAQ: NTRA) embarked on a positive trajectory last Friday, experiencing a notable 5.40% surge, culminating in the weekend session’s closure at $42.74. Notably, this surge persisted in the face of insider selling activity. In an SEC filing, it was revealed that NTRA Co-Founder Sheena Jonathan sold a sum of 6000 shares. The transactions were carried out at an average price of $40.29 per share for total proceeds of $241,501.
Furthermore, Natera (NTRA) made headlines last week with the announcement of a significant development. The Journal of the American Society of Nephrology recently published preliminary findings from the RenaCARE (Renasight Clinical Application, Review, and Evaluation) study.
This comprehensive, multi-center prospective study aimed to evaluate the prevalence and implications of genetic testing within the chronic kidney disease (CKD) population. An impressive 1,623 CKD patients were enrolled across 31 community and academic medical centers, each subjected to Natera’s Renasight genetic test, which examines 385 kidney-related genes.
The results from the RenaCARE investigation unveiled that a noteworthy 20.8% of CKD patients presented positive genetic findings. This led to transformative outcomes, with 48.8% of patients receiving novel or reclassified diagnoses and 34% obtaining insights into their disease subtype. Remarkably, 90.7% of the positively identified patients witnessed modifications in their treatment plans, with 32.9% experiencing alterations in their therapeutic strategies.
This pivotal RenaCARE study underscores the critical role of genetic testing in mitigating the inherent limitations in conventional CKD diagnostics. It conclusively demonstrates the inherent worth of genetic testing in enhancing the precision of clinical CKD diagnoses, thereby enabling healthcare providers to customize management strategies and therapeutic interventions for individual patients.
Natera’s groundbreaking study underscores the urgency of integrating genetic testing more comprehensively into the realm of kidney care, with the ultimate objective of initiating or modifying management protocols at the earliest juncture.
